Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Updated: 08/22/2023
MyCME, the leader in free medical education, offers a host of courses across all cardiovascular diseases. Access the entire library of Cardiology CME and CE for free.
The top cardiology CME courses available now on www.myCME.com include topics on mitral stenosis, anemia, cardiac arrhythmia, and more.
Cardiology CME Course 1 | Integrating Non-Steroidal Mineralocorticoid Antagonist Class in Cardiorenal Medicine
Program Description
Join Drs Martha Gulati and Christos Argyropoulos and Viet Le in a roundtable discussion about screening for and treating chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). Discover which patients are at risk for developing end-stage-renal disease, including patients with elevated albuminuria and low estimated glomerular filtration rate (eGFR), and therefore how to screen patients based upon urine albumin-creatinine ration (UACR) and eGFR levels.
Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone, which is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD, are now available to protect kidney function in patients with T2D. SGLT2 inhibitors including canagliflozin and dapagliflozin have shown robust reduction in composite renal primary outcomes, and the mechanisms of SGLT2 inhibitors, angiotensin-converting enzyme inhibitors (ACEis), and angiotensin II receptor blockers (ARBs) may act in a complementary way with the non-steroidal MRAs, potentially offering further clinical benefits.
There is a risk of hyperkalemia when implementing MRA therapies for CKD in T2D, and it is necessary for clinicians to properly understand how to mitigate that risk through appropriate dietary counseling, and through the use of potassium-binding therapies, including patiromer and sodium zirconim cyclosilicate, which are indicated for reducing potassium levels, alongside other agents such as sodium polystyrene sulfonate. There is a need for clinicians to work as a multidisciplinary team while including the patient in the shared decision-making process to avoid disease progression and life-altering dialysis.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Evaluate the underlying pathophysiology, mechanisms, and appropriate guideline-based screening practices in CKD to optimize outcomes
- Summarize the efficacy and safety of novel therapies for the management of T2D and CKD to reduce the risk of adverse renal and cardiovascular outcomes
- Review best practices for the sequencing of appropriate therapy in patients with T2D and CKD based on current screening best practices, guidelines, and clinical evidence
Intended Audience
Cardiologists, Endocrinologists, Nephrologists, Primary Care Physicians, Nurse Practitioners, Nurses, Physician Assistants and other clinicians caring for patients in T2D with CKD
Commercial Supporter
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
Max Credits
- 1.00 / AMA PRA Category 1 Credit(s)
Expires: August 30, 2023
Cardiology CME/CPE Course 2 | Pneumococcal Vaccination Simplified: Which Adults Should Get It and When? – Infographic
Program Description
In January 2022, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) updated and simplified guidelines for the administration of pneumococcal vaccination in adults at risk of pneumococcal infection. Dr. Julio Ramirez and Dr. Ruth Carrico of the Norton Infectious Diseases Institute in Louisville, KY, discuss these updated guidelines and the importance of pneumococcal vaccination in at-risk adults. Disparities in the use of pneumococcal vaccination are addressed and recommendations for overcoming barriers to pneumococcal vaccination are provided.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss the scope, burden, and risks of pneumococcal disease in adults, including special populations such as the elderly and the immunocompromised
- Describe the different types of available pneumococcal vaccines, including their characteristics and logistics for use
- Outline the newly updated ACIP recommendations for pneumococcal vaccination in adults
Intended Audience
Infectious Disease Specialists, Internal Medicine, Family Practice, Geriatric Clinicians, NPs, PAs, and Pharmacists
Commercial Supporter
Supported by an educational grant from Pfizer Inc.
Max Credits
- 1.00 / AMA PRA Category 1 Credit(s)
- 1.00 / CE for Pharmacists
Expires: September 15, 2023
Cardiology CME/CPE Course 3 | Pneumococcal Vaccination Simplified: Which Adults Should Get It and When? – Podcast
Program Description
In January 2022, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) updated and simplified guidelines for the administration of pneumococcal vaccination in adults at risk of pneumococcal infection. Dr. Julio Ramirez and Dr. Ruth Carrico of the Norton Infectious Diseases Institute in Louisville, KY, discuss these updated guidelines and the importance of pneumococcal vaccination in at-risk adults. Disparities in the use of pneumococcal vaccination are addressed and recommendations for overcoming barriers to pneumococcal vaccination are provided.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Outline the newly updated ACIP recommendations for pneumococcal vaccination in adults
Intended Audience
Infectious Disease Specialists, Internal Medicine, Family Practice, Geriatric Clinicians, NPs, PAs, and Pharmacists
Commercial Supporter
Supported by an educational grant from Pfizer Inc.
Max Credits
- 0.25 / AMA PRA Category 1 Credit(s)
- 0.25 / CE for Pharmacists
Expires: September 15, 2023
Cardiology CME/CNE Course 4 | All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management
Program Description
Clinicians may be unaware of findings from late‐stage trials examining these combinations and may be hesitant to use certain therapies based on associated toxicity profiles. To help clarify misconceptions related to adverse events and ensure appropriate cardio‐oncology care when warranted, please join a panel of hematology/oncology and cardio-oncology experts to review the most up-to-date data on the care of CLL. Hear from a patient on their account of receiving upfront targeted therapy and their experience through decision-making. Panelists will share strategies to select the right upfront therapy as part of patient-centered care that maximizes long-term outcomes, ensures patient quality of life, and anticipates and manages side effects.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Review the late-stage clinical data and ongoing trials evaluating fixed-duration regimens in CLL
- Discuss patient preferences for fixed-duration therapy and strategies for patient counseling on appropriate treatment selection
- Evaluate long-term and real-world data to maximize patient outcomes
- Assess the current evidence-based guidelines and best practices for appropriate cardiovascular toxicity management across the cardio-oncology team
- Promote patient-centered care through better understanding of real-world patient experiences
Intended Audience
The intended audience for this activity are hematologic oncologists, hematologists, cardiologists, cardio‐oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Commercial Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Max Credits
- 1.00 / AMA PRA Category 1 Credit(s)
Expires: September 16, 2023
Cardiology CE Course 5 | Digital Pathway – Changing the Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, ‘High-Intensity Lipid Lowering Therapy’ to Improve Outcomes
Program Description
Patients with a recent myocardial infarction (MI) are at very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events, however, targeted LDL-C goal achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience. Despite the intensive medical management following an MI, risk of a recurrent CV event is substantial and patients with a recent MI have significant loss of productivity the year after the event. Furthermore, this burden is more pronounced in very high-risk patients, including those with a high burden of cardiometabolic comorbidities, compared to patients who are not very-high risk.
During this activity, experts will provide guidance on the individualization of statin and non-statin therapies in this setting, as well as how to address the current inertia in order to optimize outcomes. The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
Educational Objectives
After completing this activity, the participant should be better able to:
- Review current guideline recommendations for lipid testing, lipid targets, and lipid-lowering therapy in patients with a recent MI
- Explain the efficacy and safety of PCSK9 inhibitors in patients with a recent Ml and their implications for patient selection
- Describe individualized treatment strategies for very-high risk ASCVD patients with a recent Ml that prioritize the early initiation and intensification of treatment to optimize overall outcomes
Intended Audience
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Commercial Supporter
This activity is supported by educational funding provided by Amgen.
Max Credits
- 1.50 / AMA PRA Category 1 Credits
- 1.50 / ANCC Contact Hours
- 1.50 / CE for Pharmacists
- 1.50 / CPEU Credits
Expires: September 23, 2023
Cardiology CME/CNE/CPE/CPEU Course 6 | Digital Pathway – Interpreting Data on Novel MR Antagonists and Cardiorenal Outcomes for T2D and CKD
Program Description
Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this activity, experts will discuss the recent advances with nonsteroidal MRAs in patients with type 2 diabetes and CKD, as well as their potential application to patient care.
The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
Educational Objectives
After completing this activity, the participant should be better able to:
- Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
- Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
- Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
- Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.
Intended Audience
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Commercial Supporter
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / ANCC Contact Hour
- 1.00 / CE for Pharmacists
- 1.00 / CPEU Credit
Expires: September 27, 2023
Cardiology CME/CNE Course 7 | TAVR Update: Underutilization, Clinical Outcomes, Costs, and Future Directions
Program Description
Over the last 10 years, transcatheter aortic valve replacement (TAVR) rapidly became the dominant form of AVR in the United States. Nevertheless, despite beneficial clinical outcomes and cost savings with TAVR vs surgical AVR, aortic stenosis (AS) remains undertreated overall, but especially among minority populations. This panel discussion, featuring two cardiologists who are health economics researchers and an MD officer of a health insurer, provides a comprehensive update on the clinical outcomes and cost benefits of TAVR, as well as best practices for its implementation.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Describe the importance of timely intervention in patients with severe aortic stenosis
- Identify factors that impact outcomes and cost-effectiveness associated with transcatheter aortic valve replacement (TAVR) vs traditional surgical approaches
- Apply best practices to identify candidates for AVR
- Ensure that all potential candidates for TAVR, including underserved populations, are referred for evaluation by an experienced heart valve team
Intended Audience
This activity is designed to educate members of the utilization management team, as well as practicing clinicians (eg, referring cardiologists, advanced practice providers, and primary care providers) who care for patients with AS about the importance of prompt referral and timely intervention in patients who may be candidates for TAVR.
Commercial Supporter
Supported by an educational grant from Edwards Lifesciences LLC.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / ANCC Contact Hour
Expires: September 30, 2023
Cardiology CME Course 8 | Getting on Track and Staying There: Lipids and ASCVD Risk
Program Description
Early and aggressive lowering of low-density lipoprotein cholesterol (LDL-C) reduces the risk of atherosclerotic cardiovascular disease (ASCVD) events in patients with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C is estimated to lead to ~20% reduction in the relative risk of major cardiovascular events. Statins are the mainstay of hypercholesterolemia management, but many patients do not tolerate statin-based treatment, which ultimately leads to medication non-adherence, ASCVD events, and higher healthcare costs. In this webcast, faculty reviews statin and non-statin management of hyperlipidemia for primary and secondary prevention of ASCVD.
This webcast was recorded at the Emerging Challenges and Clinical Updates Live Virtual Broadcast and is being used with the permission of the presenters.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Describe the consequences of patient non-adherence and clinical inertia on atherosclerotic cardiovascular disease (ASCVD) event risk in patients with hypercholesterolemia
- Recognize the benefits of early, aggressive lipid-lowering strategies that target absolute low-density lipoprotein cholesterol (LDL-C) reduction in patients who are at high risk for or who have ASCVD
- Individualize lipid-lowering strategies to improve adherence and reduce cardiovascular risk, based on a shared patient–clinician assessment of the risks and benefits of currently available therapies
Intended Audience
Primary care physicians, nurse practitioners, physician assistants, and other clinicians managing patients with hypercholesterolemia
Commercial Supporter
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / AANP Contact hour (includes 0.75 pharmacology hours)
Expires: September 30, 2023
Cardiology CME/CNE Course 9 | Navigating the Science of EPA and DHA Omega-3s
Program Description
Omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are found in every cell of the body and are beneficial at all stages of life. Yet, 95% of Americans are not getting enough of these necessary nutrients.
In this multi-part webinar, learn from four experts in their respective areas of omega-3 research and outcomes: Dr. Carl “Chip” Lavie (MD) will explain the body of research suggesting that EPA and DHA omega-3 supplementation may help prevent coronary heart disease events and myocardial infarction, and why we need to improve upon the 5% of Americans that are getting enough EPA and DHA omega-3s to be cardioprotective.
Dr. Susan Carlson (PhD) will explain the research on omega-3s and prenatal health, particularly how maternal intake of DHA may protect against early preterm birth. Dr. Melanie Plourde (PhD) reviews the latest evidence on EPA+DHA omega-3s and cognitive health. Moderating and explaining the implications for health professionals is Robyn Kievit, NP, RD.
Clinicians viewing this webinar will be able to differentiate between the various types of omega-3 fatty acids and make recommendations to their patients on foods to eat and supplement dosages to aim for in order to obtain recommended amounts of EPA and DHA omega-3s.
Educational Objectives
After completing the educational activity, participants should be able to:
- Differentiate between ALA and EPA/DHA omega-3s and why dietary focus should be on EPA+DHA
- Make recommendations to their patients on omega-3 intake and target dosage amounts based on the latest science
- List best food sources of EPA and DHA omega-3s
Intended Audience
This activity is designed to meet the needs of Nurses, Nurse Practitioners and Physician Assistants.
Commercial Supporter
This activity is supported by an educational grant from GOED: the Global Organization for EPA and DHA Omega-3s.
Max Credits
- 1.00 / AAPA Category 1 CME Credit
- 1.00 / ANCC Contact Hour
- 1.00 / AANP Contact Hour
Expires: October 20, 2023
Cardiology CME/CE Course 10 | Beyond DAPT – DOACs for CAD & PAD
Program Description
Dual antiplatelet therapy (DAPT) is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), and single antiplatelet therapy for secondary prevention in stable patients with coronary artery disease (CAD) and peripheral artery disease (PAD). However, there remains a residual risk of ischemic events in patients with CAD and PAD. Recent clinical studies have shown that dual pathway inhibition involving an antiplatelet and a direct oral anticoagulant (DOAC) can be more effective than single pathway inhibition with antiplatelet therapy alone for these patients. While these developments can help in improving treatment outcomes for patients, clinicians may not be familiar with newer concepts such as the role of dual pathway inhibition in the management of CAD and PAD.
This course will provide clinicians with strategies to understand the role of dual pathway inhibition in the management of CAD and/or PAD, and identify patients who would benefit from additional anticoagulant therapy.
This webcast was recorded at the Conversations in Cardiology 2022 Live Virtual Broadcast and is being used with the permission of the presenters.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Review the role of dual pathway inhibition in the management of patients with CAD and PAD
- Identify patients with CAD and PAD who would benefit from additional anticoagulant therapy with DOACs
Intended Audience
Cardiologists, nurse practitioners, physician assistants, and other clinicians engaged in the care of patients with cardiovascular and peripheral arterial disease
Commercial Supporter
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / AANP Contact Hour (includes 1.00 pharmacology hour)
Expires: October 31, 2023
Top 10 Free Cardiology CME Courses
The Cardiology Advisor Institute, powered by myCME, is a specialty-based community offering cardiology CE and cardiology CME courses, resources, and news tailored and curated for you. Specialized topics include these and more:
- Homozygous familial hypercholesterolemia (HoFH)
- Mineralocorticoid receptor antagonists
- Hypertrophic cardiomyopathy (HCM)
- Atrial fibrillation and AFIB treatment
- High-sensitivity cardiac troponin (hs-cTn)
- Transcatheter aortic valve replacement (TAVR)
- Heart failure
- Heart failure with preserved ejection fraction (HFpEF)
- Pulmonary arterial hypertension (PAH)
Make sure to take advantage of this catalog of accredited free cardiology CE and CME courses for your continuing education.
Updated: 08/22/2023
